Evidence map›Paper›PMID 38152401›Full record

ArticleFrontiers in immunology2023

Novel antibody competition binding assay identifies distinct serological profiles associated with protection.

Jessica S Bolton, Randall S MacGill, Emily Locke, Jason A Regules, Elke S Bergmann-Leitner

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Discovery andFrontiers in immunology · 2025
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jessica S BoltonBiologics Research & Development, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United States.
Randall S MacGillCenter for Vaccine Innovation and Access, PATH, Washington, DC, United States.
Emily LockeCenter for Vaccine Innovation and Access, PATH, Washington, DC, United States.
Jason A RegulesBiologics Research & Development, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United States.
Elke S Bergmann-LeitnerBiologics Research & Development, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United States.
Walter Reed Army Institute of Research · USProgram for Appropriate Technology in Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pre-erythrocytic malaria vaccines hold the promise of inducing sterile protection thereby preventing the morbidity and mortality associated with Methods: We developed a novel multiplex competition assay based on well-characterized monoclonal antibodies (mAbs) that target crucial epitopes across the CSP molecule. This new tool assesses both, quality and epitope-specific concentrations of vaccine-induced antibodies by measuring their equivalency with a panel of well-characterized, CSP-epitope-specific mAbs. Results: Applying this method to RTS,S-immune sera from a CHMI trial demonstrated a quantitative epitope-specificity profile of antibody responses that can differentiate between protected vs. nonprotected individuals. Aligning vaccine efficacy with quantitation of the epitope fine specificity results of this equivalency assay reveals the importance of epitope specificity. Discussion: The newly developed serological equivalence assay will inform future vaccine design and possibly even adjuvant selection. This methodology can be adapted to other antigens and disease models, when a panel of relevant mAbs exists, and could offer a unique tool for comparing and down-selecting vaccine formulations.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAdjuvants, ImmunologicAntibodies, MonoclonalAntibodies, ProtozoanEpitopesHumansAdjuvants, ImmunologicAntibodies, MonoclonalAntibodies, ProtozoanEpitopesMalaria Vaccinesantigen-specificitycircumsporozoite proteinequivalencymalariaprotectionserologyvaccine

Identifiers

PMID38152401
PMCPMC10752609
OpenAlexW4389571391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.